Bristol-Myers Squibb Co logo

Bristol-Myers Squibb Co (BMY)

Market Closed
28 Mar, 20:00
NYSE NYSE
$
60. 02
+1.12
+1.9%
$
124.26B Market Cap
- P/E Ratio
2.4% Div Yield
10,786,600 Volume
- Eps
$ 58.9
Previous Close
Day Range
58.23 60.11
Year Range
39.35 63.33
Earnings results expected in 26 days

Summary

BMY closed yesterday higher at $60.02, an increase of 1.9% from Thursday's close, completing a monthly increase of 5.43% or $3.09. Over the past 12 months, BMY stock gained 1.04%.
BMY pays dividends to its shareholders, with the most recent payment made on Feb 03, 2025. The next announced payment will be in In 1 month on May 01, 2025 for a total of $0.62.
The last earnings report, released on Feb 06, 2025, exceeded the consensus estimates by 0.2%. On average, the company has surpassed earnings expectations by 0.32%, based on the last three reports. The next scheduled earnings report is due on Apr 25, 2025.
The stock of the company had never split.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track BMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

BMY Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Bristol-Myers Squibb Co Dividends

Bristol-Myers Squibb Co logo
BMY In 3 months
Estimated
Quarterly
$0.62 Per Share
Bristol-Myers Squibb Co logo
BMY In 5 days
Announced
Quarterly
$0.62 Per Share
Bristol-Myers Squibb Co logo
BMY 2 months ago
Paid
Quarterly
$0.62 Per Share
Bristol-Myers Squibb Co logo
BMY 5 months ago
Paid
Quarterly
$0.6 Per Share
Bristol-Myers Squibb Co logo
BMY 8 months ago
Paid
Quarterly
$0.6 Per Share
Bristol-Myers Squibb Co logo
BMY 11 months ago
Paid
Quarterly
$0.6 Per Share

Bristol-Myers Squibb Co Earnings

25 Apr 2025 (26 Days) Date
1.53
Cons. EPS
-
EPS
6 Feb 2025 Date
1.47
Cons. EPS
1.67
EPS
31 Oct 2024 Date
1.49
Cons. EPS
1.8
EPS
26 Jul 2024 Date
1.63
Cons. EPS
2.07
EPS
7 May 2024 Date
-
Cons. EPS
-
EPS
Bristol-Myers Squibb Co logo
BMY In 3 months
Estimated
Quarterly
$0.62 Per Share
Bristol-Myers Squibb Co logo
BMY In 5 days
Announced
Quarterly
$0.62 Per Share
Bristol-Myers Squibb Co logo
BMY 2 months ago
Paid
Quarterly
$0.62 Per Share
Bristol-Myers Squibb Co logo
BMY 5 months ago
Paid
Quarterly
$0.6 Per Share
Bristol-Myers Squibb Co logo
BMY 8 months ago
Paid
Quarterly
$0.6 Per Share
Bristol-Myers Squibb Co logo
BMY 11 months ago
Paid
Quarterly
$0.6 Per Share
25 Apr 2025 (26 Days) Date
1.53
Cons. EPS
-
EPS
6 Feb 2025 Date
1.47
Cons. EPS
1.67
EPS
31 Oct 2024 Date
1.49
Cons. EPS
1.8
EPS
26 Jul 2024 Date
1.63
Cons. EPS
2.07
EPS
7 May 2024 Date
-
Cons. EPS
-
EPS

Bristol-Myers Squibb Co (BMY) FAQ

What is the stock price today?

The current price is $60.02.

On which exchange is it traded?

Bristol-Myers Squibb Co is listed on NYSE.

What is its stock symbol?

The ticker symbol is BMY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 124.26B.

What is the earnings per share?

The EPS is 1.53.

When is the next earnings date?

The next earnings report will release on Apr 25, 2025.

Has Bristol-Myers Squibb Co ever had a stock split?

No, there has never been a stock split.

Bristol-Myers Squibb Co Profile

Drug Manufacturers - General Industry
Healthcare Sector
Dr. Christopher S. Boerner Ph.D. CEO
NYSE Exchange
US1101221083 ISIN
Germany Country
- Employees
4 Apr 2025 Last Dividend
7 Aug 2001 Last Split
- IPO Date

Overview

Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Products and Services

  • Eliquis: Used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Opdivo: A versatile anti-cancer medication approved for a wide range of cancers including bladder, blood, colorectal, head and neck, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lung, melanoma, mesothelioma, stomach, and esophageal cancer.
  • Pomalyst/Imnovid: Designed for the treatment of multiple myeloma, providing vital options for patients with this challenging form of cancer.
  • Orencia: Offers relief for individuals suffering from active rheumatoid arthritis and psoriatic arthritis, aiming to improve quality of life and reduce symptoms.
  • Sprycel: Specifically targeted at treating Philadelphia chromosome-positive chronic myeloid leukemia, a particular type of leukemia characterized by the presence of an abnormal chromosome.
  • Yervoy: This medication is used for the treatment of patients with unresectable or metastatic melanoma, offering a beam of hope for those battling this form of skin cancer.
  • Empliciti: Another option in the fight against multiple myeloma, providing an additional avenue for treatment for patients.
  • Abecma: Crafted for the treatment of relapsed or refractory multiple myeloma, Abecma offers a new horizon for patients who have not responded to previous treatments.
  • Reblozyl: A therapeutic option for the treatment of anemia, focusing on a condition that can severely impact the overall health and well-being of patients.
  • Opdualag: Specifically indicated for the treatment of unresectable or metastatic melanoma, enhancing the arsenal against this aggressive skin cancer.
  • Zeposia: Approved to treat relapsing forms of multiple sclerosis, this medication aims to reduce the frequency of relapses and slow the disease's progression.
  • Breyanzi: Used for the treatment of relapsed or refractory large B-cell lymphoma, Breyanzi provides a valuable tool in the fight against this type of cancer.
  • Onureg: A treatment option for acute myelogenous leukemia (AML), offering new hope for patients with this aggressive form of leukemia.
  • Inrebic: Targets myelofibrosis, a serious bone marrow disorder, by offering patients a chance for improved outcomes and symptom relief.
  • Camzyos: Focuses on the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), aimed at enhancing functional capacity and reducing symptoms in affected patients.
  • Sotyktu: Provides relief for patients suffering from moderate-to-severe plaque psoriasis, offering a new approach in managing this chronic skin condition.
  • Augtyro: Specifically developed for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), marking a significant step forward in targeted cancer therapy.
  • Revlimid: An oral immunomodulatory drug critical for the treatment of multiple myeloma, playing a key role in managing this form of cancer.
  • Abraxane: Used to treat breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer, Abraxane extends therapeutic options for patients facing these serious diseases.

Contact Information

Address: Route 206 & Province Line Road
Phone: 609 252 4621